Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almond Therapy with Esketamine in TRMDD
NCT05323019Phase 2Terminated
- Sponsor
- Zylorion
- Start
- Oct 2022
- Primary completion
- Feb 2023
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial (2 arms), sponsored by Zylorion. Primary endpoint: Montgomery Asberg Depression Rating Scale at Day 28. Started Oct 2022; status: terminated.
Beyond the preview
Go deeper on NCT05323019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323019.